Science & Technology
Heterocyclic Inhibitors of QcrB as Novel Drugs for Infections Caused by Nontuberculous Mycobacteria
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43AI188991-01
Award Ceiling
$300K
Award Floor
$300K
Close Date
Jun 30, 2027
472 days leftTotal Funding
$300K
Expected Awards
1
Posted Date
Jul 23, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R43AI188991-01
Description
SBIR Phase Phase I award: "Heterocyclic Inhibitors of QcrB as Novel Drugs for Infections Caused by Nontuberculous Mycobacteria" awarded to FIMBRION THERAPEUTICS INC in SAINT LOUIS, Missouri. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $300,001. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.